<DOC>
	<DOCNO>NCT01394796</DOCNO>
	<brief_summary>There mount evidence modulation property major catechin green tea , epigallocatechin-3-gallate ( EGCG ) , dual specificity tyrosine-phosphorylation-regulated kinase 1A ( DYRK1A ) gene overexpression brain DS mouse models.The aim investigate clinical benefit safety EGCG administration young adult DS , establish short-term EGCG effect ( three month ) neurocognitive performance , determine persistency reversibility EGCG related effect three month discontinue use .</brief_summary>
	<brief_title>Egcg , dyrk1a Inhibitor Therapeutic Tool Reversing Cognitive Deficits Down Syndrome Individuals .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Have diagnose DS neurological disease , age 1429 year , give consent participate ( official custody ) . Subjects neurological disease DS , relevant medical disease , comorbid mental disorder currently take treatment could interfere cognitive function alter key biomarkers biochemical parameter analyze . Having suffer major illness undergo major surgery last three month study ; Regular ingestion medication month precede study . Exceptions make single dos symptomatic medication administer week precede trial . Current ingestion vitamin supplement catechins AINE two week precede study . History gastrointestinal , hepatic renal problem cause may alter process absorption , distribution , metabolism , excretion drug , might suggest gastrointestinal irritation drug . Subjects follow vegetarian diet . Practice physical exercise 2 hour per day energy consume/consumption 3000 kcal per week .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>